Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 3,437 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,437 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total transaction of $83,519.10. Following the sale, the insider now owns 50,670 shares of the company’s stock, valued at $1,231,281. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $24.07 on Thursday. The company’s 50 day simple moving average is $24.18 and its two-hundred day simple moving average is $20.17. Nurix Therapeutics, Inc. has a 1 year low of $4.96 and a 1 year high of $27.60. The stock has a market capitalization of $1.71 billion, a PE ratio of -8.27 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The company had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. On average, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.84 EPS for the current year.

Institutional Trading of Nurix Therapeutics

Large investors have recently modified their holdings of the business. Amalgamated Bank raised its stake in Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after purchasing an additional 511 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Nurix Therapeutics by 77.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,388 shares of the company’s stock worth $278,000 after buying an additional 5,419 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after buying an additional 559 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock worth $101,000 after acquiring an additional 4,119 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Nurix Therapeutics during the 3rd quarter worth $3,152,000.

Analyst Ratings Changes

NRIX has been the subject of several research analyst reports. Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $41.00 price target for the company. UBS Group assumed coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $35.00 price target on the stock. Robert W. Baird initiated coverage on Nurix Therapeutics in a research note on Friday, September 6th. They set an “outperform” rating and a $26.00 price target for the company. Truist Financial began coverage on Nurix Therapeutics in a research note on Wednesday, July 31st. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Royal Bank of Canada cut their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.